An update from Nanobiotix ( (NBTX) ) is now available.
Nanobiotix announced the initiation of a Phase 2 clinical trial for JNJ-1900 (NBTXR3) targeting Stage 3 unresectable non-small cell lung cancer. This study, part of a collaboration with Janssen Pharmaceutica, aims to enhance radiotherapy treatment options, potentially expanding the application of NBTXR3 across various solid tumors.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company specializing in nanoparticle-based therapeutic approaches, primarily in oncology. Founded in 2003 and headquartered in Paris, the company is listed on Euronext Paris and Nasdaq, with a focus on innovative treatments for cancer and other significant diseases.
YTD Price Performance: 4.48%
Average Trading Volume: 33,766
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $148.6M
For detailed information about NBTX stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com